Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 14, 2001
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy," is focused on understanding the long-term effects of radiation therapy on cancer patients. The study aims to gather information about how patients are doing after treatment, including any late side effects they may experience. By collecting data from follow-up care, researchers hope to learn more about the natural progression of disease and the outcomes of different treatments.
To participate in this study, you need to be at least 18 years old and have received radiation therapy at the National Cancer Institute (NCI). You should not be part of any other active treatment research study. Participants will have their health monitored during regular follow-up visits, and some of the information collected may be used anonymously in future research publications. It's important to note that if you have any questions or concerns about your health insurance, social services will be available to help. Overall, this trial offers a valuable opportunity for patients to contribute to understanding the long-term impacts of cancer treatment.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • ROB investigator deems that it is in the best interests of the participant and the NCI/ROB for the participant to be seen in follow-up in the ROB clinic.
- • Participant is able to provide informed consent.
- • Participant must have a primary physician in the community to whom records and appropriate follow-up management can be given. Social services will be enlisted for any participants who lack health insurance, etc.
- • Participants who have received radiotherapy.
- • Age greater than or equal to 18 years of age
- EXCLUSION CRITERIA:
- • Participants who are on an interventional research protocol at NIH at the time of enrollment.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Kevin A Camphausen, M.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials